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Abstract: 
Introduction: SmartPill® (Given Imaging Corp.,Yoqneam,Israel) is an 
ingestible, non-imaging capsule that records physiological data including 
contractions and pH throughout the gastrointestinal(GI) tract. There are 
scarce data looking at SmartPill® assessment of patients with 
known/suspected small-bowel Crohn’s Disease (CD). This pilot study aims 
to investigate feasibility and safety of SmartPill® to assess gut motility in 
this group. Materials & methods: Over one year, patients with 
known/suspected CD, referred for small-bowel capsule endoscopy(SBCE), 
were invited. Patients underwent hydrogen breath test to exclude small-
bowel bacterial overgrowth, patency capsule (Agile®), and provided stool 
samples for faecal calprotectin(FC). Patients ingested PillCam®SB2 and 
SmartPill® 4 hr apart. 33 healthy controls were obtained from unpublished 
data. P<0.05 was considered statistically significant. Results: 12 patients 
were recruited (7 female/5 male, mean age 44.2 ±16.6 years). 10 
underwent complete Smartpill® examination (1 stomach retention, 1 
dropout). Pillcam® was complete in 10 (1 dropout, 1 stomach retention). 
Mean faecal calprotectin was 340 ± 307.71 mcg/g. The study group had 
longer transit times and lower gut motility index versus controls. The 
difference in motility appears statistically significant (P<0.05). Longer 
transit times for SmartPill® (not statistically significant) were possibly due 
to different capsule specifications. Limitations included Smartpill® signal 
loss (5/10 studies). Discussion: This is the first pilot to attempt combining 
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SBCE and SmartPill® to assess small-bowel CD. Data on motility in CD is 
scarce. Multimodal information can provide a clearer clinical picture. 
Despite concerns about capsule retention in CD patients, SmartPill® seems 
safe for use if a patency capsule is employed beforehand. 
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INTRODUCTION 
 
The wireless motility capsule (WMC) (SmartPill®; Given Imaging Corp., Yoqneam, Israel) is a single use, 
ingestible device [1,2]. With dimensions 26.8 x 11.7mm, it is slightly bulkier than its imaging counterpart 
(PillCam®SB Medtronic, Minnesota, USA). SmartPill® records intraluminal pH, pressure and temperature as it is 
propelled through the gastrointestinal (GI) tract. Hence, the WMC is capable of providing gut motility 
parameters i.e. gastric transit time (GTT), small-bowel transit time (SBTT), colonic transit time (CTT) and whole 
gut transit time (WGTT) non-invasively. The American and European Neurogastroenterology & Motility 
Societies recommend the use of WMC to assess suspected gastroparesis, suspected small-bowel (SB) 
dysmotility and/or CTT in chronic constipation [3]. 
 
There are only scarce data on the motility patterns in patients with known or suspected Crohn’s disease (CD). 
Furthermore, the use and clinical validity of the WMC has not been evaluated in this patient group. It is 
envisaged that future wireless investigation platforms for the digestive tract will be multimodal and versatile, 
thus able to incorporate imaging information with physiological or biochemistry data such as fecal calprotectin 
(FC), haemoglobin and gas constituents of the gastrointestinal tract. This combination data could be useful in 
the investigation and management of patients with CD. For instance, orocaecal transit time has been found to 
be prolonged in CD patients for various reasons including SB bacterial overgrowth (SBBO) whereas SBTT may 
conversely be shortened in CD patients following ileo-caecal resection; this would affect absorption of 
medications and should ideally be taken into account during drug design [4]. Therefore, we designed a pilot 
study to investigate whether WMC examination is feasible and safe in the assessment of gut motility in 
patients with known or suspected CD, and its utility compared to conventional video capsule endoscopy. 
 
METHODS 
 
Patient recruitment and study protocol 
Consecutive patients with known or suspected CD (FC>200 μg/g), referred for SB evaluation with small-bowel 
capsule endoscopy (SBCE), were invited to participate in this study. The inclusion & exclusion criteria of the 
study are summarized in Table 1. Patients who accepted the invitation and consented to participate were 
invited for a lactulose hydrogen breath test for exclusion of SB bacterial overgrowth (SBBO) and were provided 
with a kit for stool sample collection and FC measurement [CALPROLAB™ ELISA (ALP), Calpro AS, Lysaker, 
Norway; reference range <50 μg/g]. Those with a positive breath test, indicating SBBO, were excluded.  
Patients with negative SBBO breath test were invited to return a stool specimen and attend for a SB patency 
check with the AGILE® capsule (Given Imaging Corp., Yoqneam, Israel).  
The detailed flowchart of the study design is presented in Figure 1. Patients ingested consecutively the 
PillCam®SB followed, four h later, by the SmartPill®. The technical characteristics of the 2 capsules used 
(PillCam®SB and SmartPill®) are detailed in Table 2.  
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Data collection 
Data were downloaded from the recorders to the relevant workstations and analysed using proprietary 
software, i.e. RAPID® for PillCam®SB and semi-automated pressure analysis software, MotiliGI
®
 (Given®Imaging 
Corp) for SmartPill®. For the latter, results are presented in both graphical and statistical forms. PillCam® data 
include gut transit times and SB findings. The inflammation levels were quantified using the Lewis score (LS), 
which has been devised to objectively report SB inflammation in SBCE. SmartPill® data examined in this study 
were pH, transit times (GTT, SBTT, CTT and WGTT) and motility index (MI) per segment, where MI = Ln (sum of 
pressure amplitudes × number of contractions +1). The data acquired from the study group were compared to 
historical controls (healthy individuals with no known pathology obtained from unpublished data), used to 
establish the normal range for segmental and total gut transit times.  
 
Statistical analysis 
Microsoft Excel (© 2015 Microsoft) and StatsDirect (StatsDirect Ltd, Altrincham, UK) software were used for 
statistical analysis. Two-tailed Mann-Whitney U test was used for comparison of the study and control groups. 
Linear regression was used to establish any correlation between motility indices and FC or LS. P values < 0.05 
were considered statistically significant.  
 
The study was supported by a defined grant by Given®Imaging Ltd (ESGE- Given®Imaging Research grant 2011) 
and approved by the local ethics committee (ref. 12/SS/0013). 
 
RESULTS 
 
Over a 12 month period (2012), 19 patients were recruited. Three patients were excluded as their previous 
history included a known strong functional component to their symptoms which could affect gut motility 
independently of CD, including irritable bowel syndrome, chronic idiopathic intestinal pseudo-obstruction and 
cyclic vomiting. A further four patients, referred for SBCE on suspicion of CD, were also excluded as their FC 
levels were <200 μg/g. Twelve patients completed the study (7 female/5 male; mean age 44.2±16.6 years). 
Figure 2 shows the number of patients recruited, dropouts, and complete/incomplete data sets obtained. 
Clinical characteristics and per patient study results are tabulated in detail in Table 3. The differences in the 
motility of the study group vs. the control group are depicted in Table 4. Patients in our study had longer 
transit times and significantly lower gut motility when compared to the control group, Figures 3,4.  
 
The motility index (MI) in the stomach, SB and colon was significantly lower in patients with CD, as compared 
with controls, and this was statistically significant (P<0.05) for all motility indices measured throughout the 
gut. The total transit time for the WMC was longer compared with the SBCE; this could be attributed to the 
differences in the capsules’ specifications as detailed in Table 2 [1,5,6] and the difference in capsule density, 
Figure 5 [7,8]. The distribution of WGTT, FC and LS for those study subjects for whom the data were available 
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is presented in Figure 6a. Figures 6b and 6c show the linear regression between MI/FC and MI/LS, 
respectively. 
DISCUSSION 
 
This pilot study is the first to attempt dual use of SBCE and WMC in the assessment of patients with known or 
suspected CD. Currently, diagnosing CD requires a clinical evaluation and a combination of endoscopic, 
histological, radiological, and/or biochemical investigations [9]. To date, the value of SBCE in the investigation 
of CD has already been established [10]. A previous study [11], in which cine magnetic resonance enterography 
(MRE) was employed in addition to the regular MRI protocol, found that imaging areas of altered gut motility 
helped to detect more CD-specific findings. Other studies have shown that CD is associated, possibly due to 
inflammation, with delayed gastric emptying [12]. 
 
Therefore, addition of motility data in this setting could be of use [2,13], especially when first-line 
investigations are inconclusive. Compared to the traditional method of assessing GI motility with 
scintigraphy/radio-opaque markers, WMC is not associated with any radiation exposure. The concurrent use of 
SBCE and WMC shows how multimodal information can provide information not only on the mucosal 
appearances of patients with CD but also physiological motility data. However, this needs to be balanced 
against the risk of capsule retention, a feared complication in patients with CD. There was one case of stomach 
retention of the capsule. This occurred after an incomplete patency check with follow-up abdominal x-ray 
(patency capsule seen within large bowel). Limited CT scanning post-patency may be more useful in these 
patients [14]. 
 
Our patient group had significantly longer transit times compared to the controls (P <0.05 for all parameters 
measured), Table 4.  However, statistical significance should be interpreted with caution due to the small 
sample size. Other limitations in this pilot study include potential selection bias, as patients with significant SB 
inflammation were excluded due to fear of capsule retention, and the SmartPill® signal loss (resulting in 
incomplete data sets in 5/10 completed WMC examinations). It is not clear if this is due to technological 
limitations or whether the concurrent use (4h apart) of two capsules caused some radiofrequency interference 
[1,5,6]. Furthermore, we experienced difficulty in correlating data obtained by the WMC with other 
parameters such as FC and LS. This can be seen in other studies that have tried to explore relationship 
between LS and FC in patients with SB CD [15]. 
 
Take home messages 
• Physiological data obtained from the use of the SmartPill® could be of value in conjunction with 
‘conventional’ SBCE to shed more light in the pathophysiology of CD and perhaps assist in patient 
management.  However, to better help clinicians to understand and maximise use of the motility 
information, the development of a simplified interpretation system is necessary.  
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• Despite concerns about capsule retention in patients with CD, our study suggests that the SmartPill® seems 
generally safe for use in these patients, although use of a patency capsule is recommended beforehand. 
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INTRODUCTION 
 
The wireless motility capsule (WMC) (SmartPill®; Given Imaging Corp., Yoqneam, Israel) is a single use, 
ingestible device [1,2]. With dimensions 26.8 x 11.7mm, it is slightly bulkier than its imaging counterpart 
(PillCam®SB Medtronic, Minnesota, USA). SmartPill® records intraluminal pH, pressure and temperature as it is 
propelled through the gastrointestinal (GI) tract. Hence, the WMC is capable of providing gut motility 
parameters i.e. gastric transit time (GTT), small-bowel transit time (SBTT), colonic transit time (CTT) and whole 
gut transit time (WGTT) non-invasively. The American and European Neurogastroenterology & Motility 
Societies recommend the use of WMC to assess suspected gastroparesis, suspected small-bowel (SB) 
dysmotility and/or CTT in chronic constipation [3]. 
 
There are only scarce data on the motility patterns in patients with known or suspected Crohn’s disease (CD). 
Furthermore, the use and clinical validity of the WMC has not been evaluated in this patient group. It is 
envisaged that future wireless investigation platforms for the digestive tract will be multimodal and versatile, 
thus able to incorporate imaging information with physiological or biochemistry data such as fecal calprotectin 
(FC), haemoglobin and gas constituents of the gastrointestinal tract. This combination data could be useful in 
the investigation and management of patients with CD. For instance, orocaecal transit time has been found to 
be prolonged in CD patients for various reasons including SB bacterial overgrowth (SBBO) whereas SBTT may 
conversely be shortened in CD patients following ileo-caecal resection; this would affect absorption of 
medications and should ideally be taken into account during drug design [4]. Therefore, we designed a pilot 
study to investigate whether WMC examination is feasible and safe in the assessment of gut motility in 
patients with known or suspected CD, and its utility compared to conventional video capsule endoscopy. 
 
METHODS 
 
Patient recruitment and study protocol 
Consecutive patients with known or suspected CD (FC>200 μg/g), referred for SB evaluation with small-bowel 
capsule endoscopy (SBCE), were invited to participate in this study. The inclusion & exclusion criteria of the 
study are summarized in Table 1. Patients who accepted the invitation and consented to participate were 
invited for a lactulose hydrogen breath test for exclusion of SB bacterial overgrowth (SBBO) and were provided 
with a kit for stool sample collection and FC measurement [CALPROLAB™ ELISA (ALP), Calpro AS, Lysaker, 
Norway; reference range <50 μg/g]. Those with a positive breath test, indicating SBBO, were excluded.  
Patients with negative SBBO breath test were invited to return a stool specimen and attend for a SB patency 
check with the AGILE® capsule (Given Imaging Corp., Yoqneam, Israel).  
The detailed flowchart of the study design is presented in Figure 1. Patients ingested consecutively the 
PillCam®SB followed, four h later, by the SmartPill®. The technical characteristics of the 2 capsules used 
(PillCam®SB and SmartPill®) are detailed in Table 2.  
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Data collection 
Data were downloaded from the recorders to the relevant workstations and analysed using proprietary 
software, i.e. RAPID® for PillCam®SB and semi-automated pressure analysis software, MotiliGI
®
 (Given®Imaging 
Corp) for SmartPill®. For the latter, results are presented in both graphical and statistical forms. PillCam® data 
include gut transit times and SB findings. The inflammation levels were quantified using the Lewis score (LS), 
which has been devised to objectively report SB inflammation in SBCE. SmartPill® data examined in this study 
were pH, transit times (GTT, SBTT, CTT and WGTT) and motility index (MI) per segment, where MI = Ln (sum of 
pressure amplitudes × number of contractions +1). The data acquired from the study group were compared to 
historical controls (healthy individuals with no known pathology obtained from unpublished data), used to 
establish the normal range for segmental and total gut transit times.  
 
Statistical analysis 
Microsoft Excel (© 2015 Microsoft) and StatsDirect (StatsDirect Ltd, Altrincham, UK) software were used for 
statistical analysis. Two-tailed Mann-Whitney U test was used for comparison of the study and control groups. 
Linear regression was used to establish any correlation between motility indices and FC or LS. P values < 0.05 
were considered statistically significant.  
 
The study was supported by a defined grant by Given®Imaging Ltd (ESGE- Given®Imaging Research grant 2011) 
and approved by the local ethics committee (ref. 12/SS/0013). 
 
RESULTS 
 
Over a 12 month period (2012), 19 patients were recruited. Three patients were excluded as their previous 
history included a known strong functional component to their symptoms which could affect gut motility 
independently of CD, such as in the case of including irritable bowel syndrome, chronic idiopathic intestinal 
pseudo-obstruction and cyclic vomiting. A further four patients, referred for SBCE on suspicion of CD, were 
also excluded as their FC levels were <200 μg/g. Twelve patients completed the study (7 female/5 male; mean 
age 44.2±16.6 years). Figure 2 shows the number of patients recruited, dropouts, and complete/incomplete 
data sets obtained. Clinical characteristics and per patient study results are tabulated in detail in Table 3. The 
differences in the motility of the study group vs. the control group are depicted in Table 4. Patients in our 
study had longer transit times and significantly lower gut motility when compared to the control group, 
Figures 3,4.  
 
The motility index (MI) in the stomach, SB and colon was significantly lower in patients with CD, as compared 
with controls, and this was statistically significant (P<0.05) for all motility indices measured throughout the 
gut. The total transit time for the WMC was longer compared with the SBCE; this could be attributed to the 
differences in the capsules’ specifications as detailed in Table 2 [1,5,6] and the difference in capsule density, 
Figure 5 [7,8]. The distribution of WGTT, FC and LS for those study subjects for whom the data were available 
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is presented in Figure 6a. Figures 6b and 6c show the linear regression between MI/FC and MI/LS, 
respectively. 
DISCUSSION 
 
This pilot study is the first to attempt dual use of SBCE and WMC in the assessment of patients with known or 
suspected CD. Currently, diagnosing CD requires a clinical evaluation and a combination of endoscopic, 
histological, radiological, and/or biochemical investigations [9]. To date, the value of SBCE in the investigation 
of CD has already been established [10]. A previous study [11], in which cine magnetic resonance enterography 
(MRE) was employed in addition to the regular MRI protocol, found that imaging areas of altered gut motility 
helped to detect more CD-specific findings. Other studies have shown that CD is associated, possibly due to 
inflammation, with delayed gastric emptying [12]. 
 
Therefore, addition of motility data in this setting could be of use [2,13], especially when first-line 
investigations are inconclusive. Compared to the traditional method of assessing GI motility with 
scintigraphy/radio-opaque markers, WMC is not associated with any radiation exposure. The concurrent use of 
SBCE and WMC shows how multimodal information can provide information not only on the mucosal 
appearances of patients with CD but also physiological motility data. However, this needs to be balanced 
against the risk of capsule retention, a feared complication in patients with CD. There was one case of stomach 
retention of the capsule. This occurred after an incomplete patency check with follow-up abdominal x-ray 
(patency capsule seen within large bowel). Limited CT scanning post-patency may be more useful in these 
patients [14]. 
 
Our patient group had significantly longer transit times compared to the controls (P <0.05 for all parameters 
measured), Table 4.  However, statistical significance should be interpreted with caution due to the small 
sample size. Other limitations in this pilot study include potential selection bias, as patients with significant SB 
inflammation were excluded due to fear of capsule retention, and the SmartPill® signal loss (resulting in 
incomplete data sets in 5/10 completed WMC examinations). It is not clear if this is due to technological 
limitations or whether the concurrent use (4h apart) of two capsules caused some radiofrequency interference 
[1,5,6]. Furthermore, we experienced difficulty in correlating data obtained by the WMC with other 
parameters such as FC and LS. This can be seen in other studies that have tried to explore relationship 
between LS and FC in patients with SB CD [15]. 
 
Take home messages 
• Physiological data obtained from the use of the SmartPill® could be of value in conjunction with 
‘conventional’ SBCE to shed more light in the pathophysiology of CD and perhaps assist in patient 
management.  However, to better help clinicians to understand and maximise use of the motility 
information, the development of a simplified interpretation system is necessary.  
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• Despite concerns about capsule retention in patients with CD, our study suggests that the SmartPill® seems 
generally safe for use in these patients, although use of a patency capsule is recommended beforehand. 
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Legend for tables and figures 
Table 1: Inclusion and exclusion criteria 
Abbreviations: CD: Crohn’s Disease; DM: Diabetes Mellitus; FC: Faecal Calprotectin; GI: 
gastrointestinal; ICD: Implantable Cardioverter Defibrillator; PC: Patency Capsule; SB: small-bowel; 
pts: patients 
 
Table 2: Comparison between specifications of PillCam® SB2 and SmartPill® 
Table 3: Summary of clinical characteristics and findings of patients in our study 
Abbreviations: CD: Crohn’s Disease; CR: Capsule retention; Duo: Duodenum; FC: Faecal Calprotectin; 
GTT: Gastric Transit Time; LS: Lewis Score; MI: Motility Index; MS: Montreal Score; PPI: Proton Pump 
Inhibitor; SB: Small Bowel; SBCE: Small-Bowel Capsule Endoscopy; SBTT: Small-Bowel Transit Time; 
TT: Transit Times; WBTT: Whole-bowel Transit Time; WMC: Wireless Motility Capsule 
* In the case of patient 8, WBTT was taken as time to excretion of capsule in ileostomy. 
 
Table 4: Comparison of results from our patients vs controls 
For our patients, some results were not available for all patients, therefore N is given where N = 
number of patients for whom results were available. 
   Abbreviations: FC: faecal calprotectin; GTT: Gastric Transit Time; LS: Lewis Score; MI: Motility Index; 
SB: small bowel; SBTT: Small-Bowel Transit Time; WBTT: Whole-Bowel Transit Time 
 
Figure 1: Summary of study protocol 
Figure 2: Recruitment process for this study 
Figure 3: Comparison of transit times between study group and controls 
Abbreviations: Ctrl: controls; GTT: gastric transit time; SBTT: small-bowel transit time; WBTT: whole 
bowel transit time 
Figure 4: Comparison of motility index between study group and controls 
Abbreviations: Ctrl: controls; duo: duodenum; MI: Motility Index; SB: small-bowel 
Figure 5: Floating characteristics of Pillcam SB2 (left) and Smartpill (right) submerged in 400ml sterile 
water for irrigation 
Figure 6a: Distribution of WBTT, FC and LS for patients in our study for whom the relevant data sets 
were available. Each plot point represents a patient in our study with the numbers corresponding to 
patient numbers in Table 3. 
Abbreviations: FC: faecal calprotectin; LS: Lewis Score; WBTT: whole bowel transit time 
 
Figure 6b: Linear regression of FC against motility indices for patients in our study for whom the 
relevant data sets were available 
 
Figure 6c: Linear regression of LS against motility indices for patients in our study for whom the 
relevant data sets were available 
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Table 1: Inclusion and Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
 age > 18 years 
 Known diagnosis of CD, being referred for (re-) 
assessment of extent & severity of SB 
inflammation 
 Suspected CD with FC>200 µg/g 
× Pregnancy or lactation 
× Swallowing difficulties or frailty  
× Known SB strictures  
× Pacemaker/ICD in situ 
× Psychiatric history  
× Prior upper GI tract surgery (other than end-to-end 
anastomosis) 
× Known DM or other cause of metabolic gastroparesis 
× Pts on codeine/morphinoids unable or unwilling to stop 
them prior to the study 
× Lactose intolerance or egg allergy (for PC) 
× Positive hydrogen breath test 
× History of functional symptoms e.g. cyclical vomiting, 
irritable bowel syndrome 
Abbreviations: CD: Crohn’s Disease; DM: Diabetes Mellitus; FC: Faecal Calprotectin; GI: gastrointestinal; 
ICD: Implantable Cardioverter Defibrillator; PC: Patency Capsule; SB: small-bowel; pts: patients 
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Table 2: Comparison between specifications of PillCam® SB2 and SmartPill® 
Specifications PillCam® SB2 SmartPill® 
Length (mm) 26 26 
Diameter (mm) 11 13 
Battery life 8 h 5 days 
Mode of data transmission Ultra-high frequency band radio telemetry Radiofrequency-based 
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 Table 3: Summary of clinical characteristics and findings of patients in our study 
No. Age 
(years) 
Gender Indication MS (if 
known 
CD) 
FC  
(μg/g) 
SBCE findings 
Total time;GTT;SBTT 
(min) 
Findings 
LS MotilGI® 
report 
TT (min) 
WBTT;GTT;SBTT 
pH MI (segmental) 
1 49 M Known 
CD 
A2 
L1 
B1 
60 546; 125; 205 
Single aphtha,  
poor views 
135 Signal loss, 
long GTT of 
SBCE but not 
WMCs 
1667; 226; 141 
 
n/a n/a 
2 37 M Known 
CD 
A1/2 
L1 
B1 
- 516; 36; 242 
Blood in stomach, 
no mucosal 
inflammation 
0 Generally 
prolonged 
transit times, 
poor motility 
6620; 2577; 288 
 
Gastric 1.4 
SB 7.2 
Gastric 16.75 
Duo 11.60 
SB 15.18 
Caecum 12.19 
3 58 F Known 
CD 
A3 
L1 
B1 
590 683; 28; 552 
Gastric residue +++, 
lymphangiectasias, 
mucosal erythema, 
?stenosis x 2 
3810 Prolonged 
transit time 
7161; 1096; 638 
 
n/a Gastric – 
Duo 12.51 
SB – 
Caecum 14.17 
4 34 F Known 
CD 
A2 
L3 
B1p 
Insuff n/a n/a High gastric 
pH, ?pt on 
PPI 
2686; 867; 240 
 
Gastric 5.4 
SB 7.1 
Gastric 16.3 
Duo 9.89 
SB 16.24 
Caecum 14.72 
5 72 F Known 
CD 
A? 
L1 
B1 
Insuff 857; 77; 252 
Distortion of folds, 
Lymphangiectasias, 
mucosal erythema, 
multiple aphthae 
5160 Generally 
low motility 
1956; 798; 447 
 
Gastric 1.1 
SB 7.2 
Gastric 14.65 
Duo 9.19 
SB 14.16 
Caecum 12.00 
6 51 M Known 
CD 
A2 
L3 
B1 
80 436; 65; 342 
aphtha x1, 
reticulonodular 
mucosal pattern 
450 Signal loss 1609; n/a; n/a n/a n/a 
7 37 F Known 
CD 
A2 
L3 
290 384; 19; n/a  
Normal to pouch 
0 WMC not 
done – 
n/a n/a n/a 
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Colectom
y + 
ileoanal 
pouch 
B1 dropout 
8 40 F Known 
CD 
Pancolect
omy + 
ileostomy 
A2 
L3 
B1 
- 410; 10; 254 
Gastritis,  
poor views 
0 Signal loss, 
rapid transit 
time 
808*; 233; n/a 
 
n/a n/a 
9 66 F ?CD NA 970 369; n/a; n/a 
Gastric retention, 
pyloric stenosis  
n/a Data loss, CR n/a n/a n/a 
10 58 M ?CD - 320 517; 31; 169 
Mucosal oedema & 
denudation,  
? enteropathy 
280 Low motility, 
acidic SB 
1312; 167; 192 
 
Gastric 1.2 
SB 6.4 
Gastric 11.58 
Duo 11.41 
SB 15.98 
Caecum 14.61 
11 36 M ?CD - 110 234; 33; 188 
Mucosal cobblestone, 
Several aphthae 
450 Signal loss 
but normal 
transit of 
WMC 
n/a n/a n/a 
12 23 F ?CD 
 
- 300 439; 14; 327 
Aphthae x 2 
450 High gastric 
pH, very long 
colon transit  
6650; 142; 252 
 
Gastric 3.7 
SB 6.6 
Gastric 10.26 
Duo 11.31 
SB 15.77 
Caecum 11.97 
 
Abbreviations: CD: Crohn’s Disease; CR: Capsule retention; Duo: Duodenum; FC: Faecal Calprotectin; GTT: Gastric Transit Time; LS: Lewis Score; MI: Motility 
Index; MS: Montreal Score; PPI: Proton Pump Inhibitor; SB: Small Bowel; SBCE: Small-Bowel Capsule Endoscopy; SBTT: Small-Bowel Transit Time; TT: Transit 
Times; WBTT: Whole-bowel Transit Time; WMC: Wireless Motility Capsule 
* In the case of patient 8, WBTT was taken as time to excretion of capsule in ileostomy. 
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Table 4: Comparison of results from our patients vs controls 
   For our patients, some results were not available for all patients, therefore N is given where N = 
number of patients for whom results were available. 
 Patients Controls P-values 
Number 12 33  
Gender 7 F, 5 M 15 F, 18 M  
Average Age ±SD  44.25 ±16.66 years 40.85 ±16.28 years  
    
FC (µg/g) 340 ±307.71 (N=8) n/a  
LS 1073.5 ±1835.5 (N=10) n/a  
    
GTT (min) 763.25 ±821.47 (N=8) 249.61 ±167.47 0.09 
SBTT (min) 314 ±171.99 (N=7) 288.81 ±107.74 0.89 
WBTT (min) 3385.44 ±2621.03 (N=9) 1988.67 ±972.99 0.82 
    
Gastric pH 2.56 ±1.92 (N=5) 1.64 ±0.89 0.35 
SB pH 6.9 ±0.37 (N=5) 7.16 ±0.45 0.17 
    
Gastric MI 13.91 ±2.88 (N=5) 52.00 ±32.68 0.002
 
Duodenal MI 10.99 ±1.22 (N=6) 90.27 ±76.50 0.0001 
SB MI 14.55 ±1.92 (N=5) 122.48 ±65.90 0.0004 
Caecal MI 13.28 ±1.35 (N=6) 108.58 ±121.10 0.0006
 
   Abbreviations: FC: faecal calprotectin; GTT: Gastric Transit Time; LS: Lewis Score; MI: Motility Index; 
SB: small bowel; SBTT: Small-Bowel Transit Time; WBTT: Whole-Bowel Transit Time 
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Patency test: PillCam® patency capsule (Given Imaging Corp) ingested with 
10mg liquid domperidone 
Patency check with proprietary handheld scanner 
30h 
Capsule present Capsule absent 
Outpatient abdo plain film to 
confirm excretion or retention 
5-7 days before test: Discontinue the following 
 
(a) medications that alter gastric pH Proton pump inhibitors, H2 antagonists, 
antacids 
(b) medications that alter GI motility Prokinetics, antiemetics, anticholinergics, 
laxatives 
Day before test: Strict liquid diet, no bowelprep 
Day of test 
Pillcam® ingested 
4h 
SmartBar®* ingested followed by SmartPill® 
* standardised cereal bar of known caloric and nutritional content 
Communication established between receiver and SmartPill®: 
pH < 4 indicating capsule in stomach 
Patients left unit with instructions to: 
- Fast for 6h before resuming normal food and drink intake 
- Record events including meals, sleep and bowel movements 
After each bowel movement 
Wait for 1 min before flushing the toilet, then check data receiver 
Data receiver returned 
Loss of signal connection between 
capsule and data receiver 
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19 patients recruited over 1 year: 
Consecutive patients referred for SBCE with the 
indications of CD or ?CD 
12 included in final study 
3 patients: strong functional history 
4 patients: FC < 200 µg/g in suspected CD 
2 incomplete studies: 
1 patient did not undergo Smartpill® 
1 patient had capsule retention in stomach 
10 completed studies as per protocol 
excluded 
excluded 
5 incomplete data sets due to data loss 
5 complete studies with full data sets 
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Figure 3: Comparison of transit times between study group and controls  
Abbreviations: Ctrl: controls; GTT: gastric transit time; SBTT: small-bowel transit time; WBTT: whole bowel 
transit time  
75x42mm (300 x 300 DPI)  
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Figure 4: Comparison of motility index between study group and controls  
Abbreviations: Ctrl: controls; duo: duodenum; MI: Motility Index; SB: small-bowel  
82x46mm (300 x 300 DPI)  
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Figure 5: Floating characteristics of Pillcam SB2 (left) and Smartpill (right) submerged in 400ml sterile water 
for irrigation  
243x157mm (300 x 300 DPI)  
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Figure 6a: Distribution of WBTT, FC and LS for patients in our study for whom the relevant data sets were 
available. Each plot point represents a patient in our study with the numbers corresponding to patient 
numbers in Table 3.  
Abbreviations: FC: faecal calprotectin; LS: Lewis Score; WBTT: whole bowel transit time  
104x87mm (300 x 300 DPI)  
 
 
Page 22 of 23
Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany
Endoscopy international open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Figure 6b: Linear regression of FC against motility indices for patients in our study for whom the relevant 
data sets were available  
118x74mm (300 x 300 DPI)  
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Figure 6c: Linear regression of LS against motility indices for patients in our study for whom the relevant 
data sets were available  
114x74mm (300 x 300 DPI)  
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